Who are ABR-215050, tasquinimod's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-06863135 + lenalidomide, Drug: Carfilzomib + Lenalidomide + Dexamethasone, CMP 001, Glatiramer acetate (GA), FTY720, Thymosin Alpha 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abr-215050-tasquinimod.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ABR-215050, tasquinimod — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABR-215050, tasquinimod (ABR-215050, tasquinimod) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Oncology.

phase 2 Immunomodulator S100A9 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABR-215050, tasquinimod (ABR-215050, tasquinimod) — Active Biotech AB. Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABR-215050, tasquinimod TARGET	ABR-215050, tasquinimod	Active Biotech AB	phase 2	Immunomodulator	S100A9
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
CMP 001	cmp-001	Pfizer Inc.	marketed	Immunomodulatory Agent	TLR9
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Thymosin Alpha 1	Thymosin Alpha 1	Xuanwu Hospital, Beijing	marketed	Immunomodulator	T-cell maturation pathway / thymic differentiation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABR-215050, tasquinimod — Competitive Intelligence Brief. https://druglandscape.com/ci/abr-215050-tasquinimod. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab